THE VALUE OF SYSTEMIC INFLAMMATORY BIOMARKERS IN ASSESSING SEVERITY IN PATIENTS WITH CEREBRAL INFARCTION
Main Article Content
Abstract
Objective: Comparison of systemic inflammatory markers NLR, CRP, and interleukin-6 between patients with acute ischemic stroke and controls, and evaluation of the value of these inflammatory biomarkers in assessing stroke severity according to the NIHSS score. Subjects and Methods: Cross-sectional study with control group was conducted, including 113 patients with cerebral infarction and 113 control subjects. Inflammatory markers assessed comprised neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), and interleukin-6 (IL-6). Disease severity was evaluated using NIHSS score. Results: The mean age was 65.03 ± 10.75 years, with 25.7% of patients having NIHSS ≥15. NLR was higher in the patient group compared to controls (4.11 vs 2.31; p<0.001). Similarly, CRP and IL-6 levels were elevated in the patient group (7.01 vs 3.01 mg/L and 11.94 vs 4.37 pg/mL, respectively; p<0.001). NLR showed a moderate correlation with NIHSS (r=0.599, p<0.001). CRP was positively correlated with NIHSS (r=0.429, p<0.001), while IL-6 demonstrated the strongest correlation (r=0.617, p<0.001). For identifying severe cerebral infarction, NLR had an AUC of 0.823 at a cut-off of 5.66; CRP had an AUC of 0.683 at a cut-off of 9.00 mg/L; and IL-6 had an AUC of 0.712 at a cut-off of 12.06 pg/mL. Conclusion: Systemic inflammatory biomarkers IL-6 and NLR show potential utility in supporting assessment of severity in patients with cerebral infarction.
Article Details
Keywords
Cerebral infarction, inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), interleukin-6 (IL-6).
References
2. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. Journal of Leukocyte Biology. 2010;87(5):779–789. doi:10.1189/jlb.1109766.
3. Bian J, Zhang L, Li H, et al. CRP as a potential predictor of outcome in acute ischemic stroke. Biomedical Reports. 2023;18(2):17. doi:10.3892/br.2022.1588.
4. Song SY, Zhao XX, Rajah G, et al. Clinical significance of baseline neutrophil-to-lymphocyte ratio in patients with ischemic stroke or hemorrhagic stroke: an updated meta-analysis. Frontiers in Neurology. 2019;10:1032. doi:10.3389/fneur.2019.01032.
5. Zhu F, Li X, Chen Y, et al. Correlations between NLR, NHR, clinicopathological characteristics and prognosis of acute ischemic stroke. Medicine (Baltimore). 2023;102(24):e33957. doi:10.1097/MD.0000000000033957.
6. Papadopoulos A, Palaiodimou L, Ntaios G, et al. Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98(10):e1002–e1012. doi:10.1212/WNL.0000000000200002.
7. Shaafi S, Sharifipour E, Rahmanifar R, et al. Interleukin-6, a reliable prognostic factor for ischemic stroke. Iranian Journal of Neurology. 2014;13(2):70–76. (No DOI assigned).
8. Bushnell C, Howard VJ, Lisabeth L, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2024;55(12):e344–e424. doi:10.1161/STR.0000000000000462.
9. Jorepalli V, Reddy V, Prasad S, et al. Association between neutrophil-lymphocyte ratio and stroke severity using the NIHSS among patients in a tertiary care hospital. Journal of Rare Cardiovascular Diseases. 2025;5(3):234–240. (DOI currently not indexed).
10. Jiang Y, Fan T. IL-6 and stroke recurrence in ischemic stroke. Biomarkers in Medicine. 2024;18(17-18):739–747. doi:10.2217/bmm-2024-0183.